PT1137436E - Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 - Google Patents

Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 Download PDF

Info

Publication number
PT1137436E
PT1137436E PT99965991T PT99965991T PT1137436E PT 1137436 E PT1137436 E PT 1137436E PT 99965991 T PT99965991 T PT 99965991T PT 99965991 T PT99965991 T PT 99965991T PT 1137436 E PT1137436 E PT 1137436E
Authority
PT
Portugal
Prior art keywords
ctla
self antigens
stimulation
blocking agents
against self
Prior art date
Application number
PT99965991T
Other languages
English (en)
Inventor
James Patrick Allison
Arthur A Hurwitz
Andrea Vanelsas
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT1137436E publication Critical patent/PT1137436E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
PT99965991T 1998-12-03 1999-12-03 Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 PT1137436E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11076198P 1998-12-03 1998-12-03

Publications (1)

Publication Number Publication Date
PT1137436E true PT1137436E (pt) 2008-09-15

Family

ID=22334796

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99965991T PT1137436E (pt) 1998-12-03 1999-12-03 Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4

Country Status (11)

Country Link
EP (1) EP1137436B1 (pt)
JP (1) JP5341287B2 (pt)
AT (1) ATE397457T1 (pt)
AU (1) AU774962B2 (pt)
CA (1) CA2352783C (pt)
CY (1) CY1108318T1 (pt)
DE (1) DE69938871D1 (pt)
DK (1) DK1137436T3 (pt)
ES (1) ES2308857T3 (pt)
PT (1) PT1137436E (pt)
WO (1) WO2000032231A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CN1371416B (zh) * 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
AU7309601A (en) 2000-06-28 2002-01-08 Genetics Inst Pd-l2 molecules: novel pd-1 ligands and uses therefor
DK2206517T3 (da) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
CN1240436C (zh) * 2002-08-28 2006-02-08 上海益众生物技术有限公司 成骨生长肽与粒细胞集落刺激因子在造血方面的协同作用
WO2004081021A2 (en) * 2003-03-12 2004-09-23 Duke University Oligonucleotide mimetics
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7494779B2 (en) 2004-06-14 2009-02-24 Li-Te Chin Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
ES2608316T3 (es) 2005-06-08 2017-04-07 Dana-Farber Cancer Institute, Inc. Métodos y composiciones para el tratamiento del cáncer e infecciones persistentes mediante la inhibición de la ruta de la muerte celular 1 (PD-1) programada
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
JP5960597B2 (ja) 2009-09-30 2016-08-02 メモリアル スローン−ケタリング キャンサー センター 癌治療のための併用免疫療法
US8435516B2 (en) 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
CN104284674A (zh) * 2012-05-04 2015-01-14 辉瑞公司 ***相关抗原及基于疫苗的免疫治疗疗法
US20150118244A1 (en) 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN111167008A (zh) 2013-12-05 2020-05-19 免疫***公司 利用射频电学膜击穿（rf-emb）的癌症免疫疗法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
DK3240801T3 (da) 2014-12-31 2021-02-08 Checkmate Pharmaceuticals Inc Kombinationstumorimmunterapi
KR20230164243A (ko) 2015-03-23 2023-12-01 조운스 테라퓨틱스, 인크. Icos에 대한 항체
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
WO2017070423A1 (en) 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP2019503398A (ja) * 2016-01-15 2019-02-07 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー がんの免疫学的処置
JP6992068B2 (ja) 2016-12-07 2022-02-03 アジェナス インコーポレイテッド 抗ｃｔｌａ－４抗体およびそれらの使用方法
US20190382490A1 (en) 2017-02-28 2019-12-19 Bristol-Myers Squibb Company Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
EP3781596A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
US20210236694A1 (en) * 2018-05-03 2021-08-05 The Johns Hopkins University Induction of anti-tumoral immune microenvironments
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
KR20210091710A (ko) 2018-10-12 2021-07-22 젠코어 인코포레이티드 PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도
WO2021067863A2 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
JP7405361B2 (ja) 2019-10-21 2023-12-26 東亞合成株式会社 抗腫瘍ペプチドおよびその利用
JP2021120355A (ja) 2020-01-30 2021-08-19 東亞合成株式会社 Ｃｔｌａ４とｂ７タンパク質との結合を抑制するペプチドおよびその利用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AU6703198A (en) * 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
CN1371416B (zh) * 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用

Also Published As

Publication number Publication date
DE69938871D1 (de) 2008-07-17
EP1137436B1 (en) 2008-06-04
WO2000032231A1 (en) 2000-06-08
ATE397457T1 (de) 2008-06-15
EP1137436A1 (en) 2001-10-04
DK1137436T3 (da) 2008-10-13
JP5341287B2 (ja) 2013-11-13
JP2002531416A (ja) 2002-09-24
CA2352783A1 (en) 2000-06-08
CY1108318T1 (el) 2014-02-12
ES2308857T3 (es) 2008-12-01
CA2352783C (en) 2012-04-10
AU2164900A (en) 2000-06-19
AU774962B2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
PT1137436E (pt) Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
ZA944347B (en) The use of cetrorelix and other nona- and decapeptides in the preparation of a medicament for combating aids and for growth stimulation
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
EP1025856A3 (en) Methods for modulating T Cell unresponsiveness
WO1997002046A3 (de) Saccharid-konjugate
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
ATE420175T1 (de) C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
EP0959896A4 (en) COMPOSITIONS BASED ON THE HUMAN THYROTROPIN RECEPTOR AND THEIR USE
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
FR2772622B1 (fr) Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur et/ou cardioverteur, de type multisite configurable
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
AU8239298A (en) Nucleotide-comprising composition
CA2194485A1 (en) Endothelial lining effects and treatment of vasospastic disorders
FR2774916B1 (fr) Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur et/ou cardioverteur, de type multisite
IL131478A0 (en) Methods for treatment of scar tissue
ES2154290T3 (es) Estimulacion de la diferenciacion celular por sindecano.
GB0102145D0 (en) Substances
GB2204497A (en) Electrode assembly for transdermal drug delivery
PL330535A1 (en) Novel systems for transcutaneous administration of trimegestone, method of preparing them for use and their application as therapeutic agents
HK1046847A1 (en) Pharmaceutical combination with analgesic action containing paracetamol and buspirone.
FR2786699B1 (fr) Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles